华东医药：第三季度净利润9.33亿元 同比增长7.71%

Core Viewpoint - Huadong Medicine (000963) reported a steady growth in revenue and net profit for Q3 2025, indicating a positive performance trajectory in the pharmaceutical industry [1] Financial Performance - Q3 2025 revenue reached 10.989 billion yuan, a year-on-year increase of 4.53% [1] - Q3 2025 net profit was 933 million yuan, reflecting a year-on-year growth of 7.71% [1] - For the first three quarters of 2025, total revenue was 32.664 billion yuan, up 3.77% year-on-year [1] - Net profit for the first three quarters of 2025 stood at 2.748 billion yuan, with a year-on-year increase of 7.24% [1] - Basic earnings per share were reported at 1.5682 yuan [1] Product and Service Performance - Revenue from innovative product sales and agency services grew by 62% year-on-year [1] - The core subsidiary of the pharmaceutical industrial sector, Sino-American Huadong, saw a net profit increase of 15.62% year-on-year [1]